DUBLIN, Calif.--(BUSINESS WIRE)--SuperGen Inc., (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced as part of a series of presentations at the 100th Annual Meeting of the American Association for Cancer Research (AACR), that it has identified a new class of small molecules which successfully inhibit Etk/Bmx kinase in preclinical cancer models (Abstract No. 3745).
